Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for MedTech Solutions's Debt-to-EBITDA or its related term are showing as below:
WAR:MDT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.93 Med: -1.1 Max: -0.09
Current: -0.17
During the past 12 years, the highest Debt-to-EBITDA Ratio of MedTech Solutions was -0.09. The lowest was -1.93. And the median was -1.10.
WAR:MDT's Debt-to-EBITDA is ranked worse than 100% of 910
companies
in the Retail - Cyclical industry
Industry Median: 2.305
vs WAR:MDT: -0.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MedTech Solutions Debt-to-EBITDA Related Terms
MedTech Solutions Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for MedTech Solutions's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDT vs AMZN, BABA, PDD: Debt-to-EBITDA Comparison
For the Internet Retail subindustry, MedTech Solutions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedTech Solutions Debt-to-EBITDA vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, MedTech Solutions's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedTech Solutions's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
MedTech Solutions (WAR:MDT) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MedTech Solutions. According to the industry distribution chart, MedTech Solutions ranks #999999 out of 910 companies in the Retail - Cyclical industry.
Is MedTech Solutions' Debt-to-EBITDA too high?
MedTech Solutions' current Debt-to-EBITDA is 0.00. Based on the distribution chart, MedTech Solutions ranks #999999 out of 910 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, MedTech Solutions has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MedTech Solutions' Debt-to-EBITDA compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, MedTech Solutions ranks #999999 out of 910 companies for Debt-to-EBITDA. This places MedTech Solutions in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Retail - Cyclical company?
The median Debt-to-EBITDA among Retail - Cyclical companies is 2.31, based on 910 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MedTech Solutions. For the Retail - Cyclical industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedTech Solutions's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedTech Solutions stock overvalued right now?
Based on GuruFocus' analysis, MedTech Solutions (WAR:MDT) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.04, compared to a current price of zł0.38 — trading 845% above its estimated fair value. The current Debt-to-EBITDA is 0.00. MedTech Solutions' overall GF Score™ is 40/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MedTech Solutions (WAR:MDT), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedTech Solutions (WAR:MDT) Overvalued in 2026?
Based on GuruFocus' analysis, MedTech Solutions stock appears to be overvalued.
The current stock price of zł0.38 is trading 845% above its estimated GF Value™ of zł0.04.
GuruFocus considers MedTech Solutions to be Significantly Overvalued.
Key valuation signals for WAR:MDT:
Debt-to-EBITDA: 0.00
GF Value™: zł0.04 vs. price of zł0.38 (845% above fair value)
No single metric tells the full story. See the WAR:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedTech Solutions SA formerly E-shopping Group SA main activity is based on conducting business through its own e-shops that operate in the dropshipping sales model.
40GF Score
Get the complete analysis for WAR:MDT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDT has been successfully added to your 
